Ganguly, P.; Macleod, T.; Wong, C.; Harland, M.; McGonagle, D.
Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i). Pharmaceuticals 2023, 16, 1286.
https://doi.org/10.3390/ph16091286
AMA Style
Ganguly P, Macleod T, Wong C, Harland M, McGonagle D.
Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i). Pharmaceuticals. 2023; 16(9):1286.
https://doi.org/10.3390/ph16091286
Chicago/Turabian Style
Ganguly, Payal, Tom Macleod, Chi Wong, Mark Harland, and Dennis McGonagle.
2023. "Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i)" Pharmaceuticals 16, no. 9: 1286.
https://doi.org/10.3390/ph16091286
APA Style
Ganguly, P., Macleod, T., Wong, C., Harland, M., & McGonagle, D.
(2023). Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i). Pharmaceuticals, 16(9), 1286.
https://doi.org/10.3390/ph16091286